In Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Receives FDA approval to expand U.S. clinical studies of its Sentinel 2000 and 2010 implantable cardioverter defibrillator systems and AngeFlex dual pass lead system to 35 centers -- adding 10 additional sites. The Minneapolis firm also has received approval to include the Sentinel 2011 and 2012 in its clinical studies. U.S. clinical testing of the Sentinel line began in March 1996 ("The Gray Sheet" Feb. 26, 1996, I&W-16). The company received CE Mark approval in 1996 for its 2000 and 2010 ICD systems and is seeking CE Mark for the 2011 and 2012...
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.